We describe a case of a 40-year-old male patient who was found to have multiple myeloma with spontaneous tumour lysis syndrome (TLS), following a compression fracture of the L-2 vertebrae. Multiple myeloma was confirmed by bone marrow analysis and the M-band on serum protein electrophoresis. Hyperuricaemia (26.2 mg/dL), hyperkalaemia (> 7.0 mEq/L), hyperphosphatemia (16.2 mg of phosphorus/dL), normocalcemia and acute kidney injury, prior to anticancer treatment suggested spontaneous TLS. Inciting events for tumour lysis, such as chemotherapy, dehydration and exposure to steroids were absent. Patient received hydration, hypourecemic drugs and haemodialysis. This case report highlights the rare presentation of multiple myeloma with spontaneous TLS.
Background
Spontaneous tumour lysis syndrome (STLS) is a rare oncologic emergency resulting in disturbed homeostasis from an unknown aetiology which occurs prior to anticancer treatment. STLS is characterised by hyperuricaemia, hyperkalaemia, secondary hypocalcaemia, metabolic acidosis, acute renal failure and absence of hyperphosphatemia. 1 Occurrences of STLS have been documented in settings of leukaemia, lymphoma and solid tumours 2, 3 and have been associated with worse outcomes.
We report a case of a middle aged male with multiple myeloma presenting with STLS. To our knowledge, this is the first case of STLS being reported in multiple myeloma.
Case details
A 40-year-old male cultivator presented with extreme fatigue, vomiting, breathlessness and decreased urine output for last one day. Examination showed pallor, tachycardia, blood pressure (130/70 mm Hg), respiratory rate (28/min) and SpO2 on room air (76%), bibasilar lung crepitations and moderate splenomegaly. Arterial blood gas analysis showed metabolic acidosis and hypoxia. A chest radiograph was suggestive of pulmonary oedema. Table 1 summarises the relevant laboratory tests done. The patient had reported to us one week before admission with a two-week history of fever, fatigue, low backache, a healed herpes zoster lesion (D4 dermatomal distribution in the right chest), gross pallor, moderate splenomegaly and mild hepatomegaly. A preliminary evaluation showed prerenal azotemia, the 'M-band' on serum protein electrophoresis and raised IgG immunoglobulin (5835 In view of severe hyperkalaemia, hyperuricaemia, normocalcemia, hyperphosphatemia and acute kidney injury (Table 1 ) before administration of anticancer chemotherapy, a diagnosis of STLS was made. He received anti-hyperkalaemic measures, the hypouricaemic drug 'allopurinol' 600 mg/day orally (300 mg/m 2 /day) and intravenous hydration. Haemodialysis was initiated with clinical improvement. After three sessions, blood urea (69 mg/dL) and serum creatinine (3.4 mg/dL) levels improved over 15 days. Palliative radiotherapy at a dose of 30 Gy over 10 fractions was initiated for the compression fracture of the L-2 vertebrae, but stopped after the fourth exposure because of severe thrombocytopenia, leukocytosis and hyperbilirubinemia. At this stage, the patient took discharge against medical advice.
Discussion
TLS is a life-threatening, rare conformation of metabolic disturbances occurring in about 5-20% of all malignancies. 5 Precise information about the epidemiology of spontaneous TLS is not available in literature and its occurrence in multiple myeloma setting has not been reported. Multiple myeloma at the age of 40 years or below, itself is a rare occurrence (about 2%). 6 The coincidence of two such rare medical complications makes this case unique and interesting.
A rise in serum uric acid > 15 mg/dL and serum phosphate > 8 mg/dL, along with acute kidney injury in patients with a large tumour burden should raise a suspicion of TLS. 1 In acute kidney injury without TLS, serum uric acid and phosphate levels are found to be less than 12 mg/dL and 6 mg/dL respectively. 1 Disproportionately high levels of serum uric acid and phosphate levels of 26.2 mg/dL and 16.2 mg/dL respectively seen in the present case were pointers towards underlying TLS.
Although the patient was diagnosed to have multiple myeloma, TLS was not an anticipated event since chemotherapy had not been started. The exact aetiology of STLS is not known till date, although an increased production of glucocorticoids and hyperthermia has been hypothesised to cause increased tumour lysis. 2 However this explanation seems to be inappropriate in this setting of multiple myeloma and thorough research needs to be done to understand the aetiology of STLS in multiple myeloma.
Furthermore, the finding of hyperphosphatemia in this case is in contrast with the fact that it occurs only in posttreatment TLS and not in spontaneous/pre-treatment TLS. 1 One of the obvious explanations for hyperphosphatemia seems to be a low mitotic rate of myeloma cells, which results in less reutilization of the released intracellular phosphate leading to its accumulation in the extracellular spaces following tumour lysis. High serum calcium level is usually seen in multiple myeloma condition which occurs due to an increased bone destruction rate. The normocalcaemia observed here may represent a balance between multiple myeloma causing hypercalcaemia and STLS causing secondary hypocalcaemia.
This case highlights the prompt recognition of STLS in multiple myeloma, which is extremely rare in tumours with an indolent course like multiple myeloma. It is important to be aware of the possibility of tumour lysis prior to initiation of treatment as it may lead to an oncological emergency. A high index of suspicion, prompt recognition and aggressive treatment with intravenous hydration, administration of hypourecaemic drugs like rasburicase or allopurinol and judicious haemodialysis are critical for successful outcome.
